Fibrosis

NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.

Retrieved on: 
Wednesday, May 1, 2024
Class Action Lawsuit, Professional Services, Legal, Sale, FDA, Lead, Cirrhosis, Fatty liver disease, LLP, EFX, News, NASH, 8-K, District court, HERE, Patient, Non-alcoholic fatty liver disease, Histology, Fibrosis, Drug development, Therapy, Pharmaceutical industry

The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) ( NASDAQ: AKRO ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) ( NASDAQ: AKRO ).
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024

Retrieved on: 
Thursday, April 11, 2024
Neoplasm, Cancer, Inflammation, CRISPR, Poster, AACR2, IND, Drug discovery, Disease, CRISPR interference, Patient, CMC, Fibrosis, Macrophage, LILRB1, AACR, MHC, LILRB2, Cell potency, NK, Pharmaceutical industry

MACO-355 is a novel, non-ligand blocking, pan-LILR targeting antibody capable of mediating macrophage reprogramming under immune suppressive conditions.

Key Points: 
  • MACO-355 is a novel, non-ligand blocking, pan-LILR targeting antibody capable of mediating macrophage reprogramming under immune suppressive conditions.
  • This new mode of action results in increased antibody activity as measured by macrophage reprogramming (cytokine release) and T cell activation.
  • The antibody also induces tumour cell phagocytosis and NK cell tumour kill independent of the ligand status of the tumour cells, unlike ligand blocking antibodies.
  • Data presented also showed that it reverts M2 (TGFβ/IL-10/IL-4) macrophage mediated suppression of T cell activity in vitro and slows tumour growth in vivo.

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

Retrieved on: 
Thursday, April 25, 2024
FDA, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Optical, Retina, USP, EDT, Retinitis pigmentosa, Food, Research, Alcoholic hepatitis, RASP, Spleen, Development, Obesity, Duke University, Liver, Patient, Erosion, Fibrosis, Multimedia, Assistant, Clinical trial, Atopic dermatitis, Therapy, Quality of life, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240425445928/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240425445928/en/
    Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis.
  • In the diet-induced model of obesity, ADX-629 decreased weight and fat mass alone and in combination with a GLP-1 agonist.
  • In the carrageenan model of inflammatory pain, ADX-246 increased tolerance to mechanical and thermal pain, and decreased joint swelling.
  • Consistent with previously released data from ADX-629 in a model of alcoholic hepatitis, ADX-246 reduced levels of fibrosis and fat in liver.

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Retrieved on: 
Thursday, April 25, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Pain, Sarcoidosis, Inflammation, Granuloma, Research, GM-CSF, Disease, Patient, Fatigue, Fibrosis, Lung, Namilumab, Clinical trial, Prednisone, Methotrexate, Pharmaceutical industry

Roivant (Nasdaq: ROIV) and Kinevant Sciences , a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).

Key Points: 
  • Roivant (Nasdaq: ROIV) and Kinevant Sciences , a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung).
  • Potentially supportive of registration, RESOLVE-Lung is a randomized, double-blind, placebo-controlled Phase 2 study designed to enroll a minimum of 100 pulmonary sarcoidosis patients whose disease is not well-controlled despite currently available treatment options.
  • “Completing enrollment for this study is an important milestone in our journey to develop a new therapy for those living with pulmonary sarcoidosis.
  • Thus, namilumab has the potential to be the only well-tolerated and effective therapy for sarcoidosis, as well as the first therapy approved specifically for pulmonary sarcoidosis.

Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment

Retrieved on: 
Tuesday, April 23, 2024
Biotechnology, Health, Oncology, Cancer, Pancreatic cancer, Tumor microenvironment, Breast, SCC, Patient, Fibrosis, Interim, Therapy, Quality of life, TME, Lung cancer, Pharmaceutical industry

Under the guidance of Board Member and Interim CEO, Jeffrey Glazer , Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment (TME).

Key Points: 
  • Under the guidance of Board Member and Interim CEO, Jeffrey Glazer , Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment (TME).
  • The launch of Aubex Therapeutics marks a pivotal moment in the ongoing effort to develop more effective cancer treatments.
  • Headquartered in San Diego, CA, Aubex Therapeutics, Inc. is a biotechnology leader dedicated to advancing oncology treatment.
  • Guided by industry veterans, Aubex focuses on novel therapies that improve the dynamics of the tumor microenvironment.

$3.8 Bn Portable Ultrasound Market - Global Forecast to 2031: Emerging Economies and Increasing Preference for PoC Testing to Provide Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Medical Devices, Health, USD, Conditional sentence, Hospital, Kidney, ACC, OB/GYN, Breast cancer, CVD, Pregnancy, DSM-IV codes, 3D, Intensive care unit, Incidence, Liver, MSK, Patient, Ambulatory care, Operating, POCUS, Physician, EDS, Doppler effect, Uterus, Diagnosis, Fibrosis, 2D, Ageing, Intensive care medicine, Growth, Medical imaging

The portable ultrasound market is expected to reach $3.8 billion by 2030, at a CAGR of 7.9% from 2024 to 2031.

Key Points: 
  • The portable ultrasound market is expected to reach $3.8 billion by 2030, at a CAGR of 7.9% from 2024 to 2031.
  • The growing preference for portable ultrasound devices over standard ultrasound machines among healthcare professionals is expected to create growth opportunities for players operating in this market.
  • Based on display, the portable ultrasound devices are further segmented into color ultrasound and black & white (B/W) ultrasound.
  • In 2024, the hospitals & clinics segment is expected to account for the largest share of the global portable ultrasound market.

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Retrieved on: 
Monday, April 22, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Idiopathic pulmonary fibrosis, Cell, Rubedo, IAG, Tissue, IPF, Khosla Ventures, Disease, Therapy, CIRM, Shanda, Fibrosis, General partnership, Multimedia, Notifiable disease, Ageing, Inflammation, Quality of life, Vaccine

Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round.

Key Points: 
  • Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $40M Series A financing round.
  • The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors.
  • “We’re delighted to attract this top-tier syndicate co-led by Khosla Ventures and Ahren Innovation Capital.
  • This significant influx of financing will allow us to advance our first clinical candidate into human studies,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
Wednesday, April 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Retrieved on: 
Tuesday, April 23, 2024
Third Rock Ventures, Factorization of polynomials, University, Cancer, Flare, Immunology, Biostatistics, Hospital, Pharmacovigilance, ACRS, Arena, GSK plc, Cardiology, Head, Virology, Pharmacy, Science, Bristol Myers Squibb, Neurology, Acquisition, DSM-IV codes, Public key certificate, Fibrosis, Arena Pharmaceuticals, Harvard Medical School, Pfizer, BMS, Internal medicine, FRCP, Drug development, Therapy, Massachusetts General Hospital, Biotechnology, Growth, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.

Key Points: 
  • CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately.
  • Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies.
  • He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
  • Dr. Manion joins Flare Therapeutics from Aclaris Therapeutics, Inc. (NASDAQ: ACRS), where he was President and Chief Executive Officer.